Table 2.
Diagnostic performance of the Panbio rapid antigen test
| Group | Test pairs | Prevalence of COVID-19 positivity (%) (RT-PCR) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|---|---|---|---|---|---|---|
| All | 1060 | 44.6 | 54.2 (51.2–57.2) | 98.5 (97.7–99.2) | 96.6 (95.5–97.7) | 72.8 (70.2–75.5) |
| First week of symptoms | 710 | 38.7 | 69.1 (65.7–72.5) | 98.4 (97.5–99.3) | 96.5 (95.1–97.8) | 83.4 (80.7–86.2) |
| 2nd week of symptoms | 147 | 68.7 | 43.6 (35.3–51.5) | 97.8 (95.4–100) | 97.8 (95.4–100) | 44.1 (36.1–52.1) |
| More than 1 week of symptoms | 203 | 68.5 | 36.7 (30.1–43.3) | 98.4 (96.7–100) | 98.1 (96.2–100) | 41.7 (34.9–48.5) |
| No symptoms | 146 | 39.0 | 26.3 (19.1–33.4) | 98.9 (97.2–100) | 93.8 (89.8–97.7) | 67.7 (60.1–75.3) |
| Symptoms* | 908 | 45.5 | 58.1 (54.9–61.3) | 98.4 (97.6–99.2) | 96.8 (95.6–97.9) | 73.8 (70.9–76.7) |
PPV = positive predictive value, NPV = negative predictive value, RT-PCR = reverse transcription-polymerase chain reaction. Test pairs include a Panbio rapid antigen test and RT-PCR with minutes of each other, obtained from 1060 patients, one per patient.